Paediatric cancer hospital St. Jude Children's Research Hospital reported on Monday that it intends to develop a USD412m 625,000-square-foot advanced cancer research centre at its campus.
Slated to break ground in spring 2018 and open in 2021, the advanced research centre is a major component of the company's USD1bn capital expansion plans. The new centre will house cutting-edge technologies and resources that can transform science and accelerate the pace of discovery. The exploration and discovery centre will cultivate transformative research and collaboration and attract scientists and clinicians.
The company's new advanced research centre will treat childhood cancer and other life-threatening diseases. The interactive and interdisciplinary environment is designed specifically for generating new ideas and teamwork. Its labs and spaces will enable researchers to collaborate openly and across departments.
In addition, the company's new advanced research centre will feature state-of-the-art labs focusing on immunology, neurobiology, cell and molecular biology, gene editing, metabolomics, advanced microscopy, epigenetics, genomics, immunotherapy as well as RNA biology.
Developed by The Crump Firm, lead architect on the project and Jacobs Engineering, experts in lab design, the advanced research center propels St. Jude for the long term, accommodating growth for the next 20 years and beyond, with two of eight floors slated for future expansion and evolving technology.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma